Givinostat (ITF2357)
99%
- Product Code: 100642
CAS:
732302-99-7
| Molecular Weight: | 475.97 g./mol | Molecular Formula: | C₂₄H₂₇N₃O₄HClH₂O |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD28502062 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Givinostat is primarily investigated for its potential therapeutic applications in various medical conditions. It is being studied as a treatment for Duchenne muscular dystrophy (DMD) due to its ability to reduce inflammation and muscle degeneration. The compound has shown promise in improving muscle function and slowing disease progression in preclinical and clinical trials. Additionally, Givinostat is explored for its efficacy in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, by modulating immune responses and reducing inflammation. It is also being researched in oncology for its potential to inhibit cancer cell growth and induce apoptosis in certain types of cancers, including hematologic malignancies. Furthermore, Givinostat has been evaluated for its role in managing chronic inflammatory conditions and rare genetic disorders, offering hope for patients with limited treatment options. Ongoing clinical trials continue to assess its safety and effectiveness across these diverse applications.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿3,969.00 |
+
-
|
Givinostat (ITF2357)
Givinostat is primarily investigated for its potential therapeutic applications in various medical conditions. It is being studied as a treatment for Duchenne muscular dystrophy (DMD) due to its ability to reduce inflammation and muscle degeneration. The compound has shown promise in improving muscle function and slowing disease progression in preclinical and clinical trials. Additionally, Givinostat is explored for its efficacy in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, by modulating immune responses and reducing inflammation. It is also being researched in oncology for its potential to inhibit cancer cell growth and induce apoptosis in certain types of cancers, including hematologic malignancies. Furthermore, Givinostat has been evaluated for its role in managing chronic inflammatory conditions and rare genetic disorders, offering hope for patients with limited treatment options. Ongoing clinical trials continue to assess its safety and effectiveness across these diverse applications.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :